All In Biotech

Drug Trial Radar · NCT04162210

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

325

Actual

Start

Apr 2, 2020

Primary completion

Sep 12, 2022

Study completion Mar 11, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Belantamab mafodotin will be administered.

  • Pom/dex (Pomalidomide plus low dose Dexamethasone)Drug

    Pomalidomide and Dexamethasone will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)Time frame: Up to 27 months

Locations

136 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Pueblo, Colorado

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Clifton Park, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Corvallis, Oregon

  • GSK Investigational Site

    Eugene, Oregon

  • GSK Investigational Site

    Tyler, Texas

  • GSK Investigational Site

    Milwaukee, Wisconsin

  • GSK Investigational Site

    St Albans, Australia

  • GSK Investigational Site

    Gosford NSW, New South Wales, Australia

  • GSK Investigational Site

    Liverpool, New South Wales, Australia

  • GSK Investigational Site

    St Leonards, New South Wales, Australia

  • GSK Investigational Site

    Woodville, South Australia, Australia

  • GSK Investigational Site

    Hobart, Tasmania, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Geelong, Victoria, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Bruges, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Kortrijk, Belgium

  • GSK Investigational Site

    Yvoir, Belgium

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Fortaleza, Brazil

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Pleven, Bulgaria

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.